A startup developing therapeutics for chronic hepatitis B and other diseases
ausperbio.comSan Francisco, USABiotechFounded 2019
8 sources · checked 1 time, last 42d ago
The company release says an unnamed strategic investor led the financing and names RA Capital as a participant; Fierce says RA Capital led. The company release takes precedence.
1 source
Sources agree.
Published by hand (finsmes.com): "HomeUSAAusperBio Raises $63M in Series B2 Funding": Checked by hand: FinSMEs states the $63M Series B2.
1 source
The source's page date is 2025-05-29, but the company's press-release dateline is May 28, 2025, which fixes the announcement date. The round was led by an unnamed existing industry-leading VC investor, so no named lead is listed; the six named firms are described as participating investors.
Published by hand (ausperbio.com): "AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B": Checked by hand: AusperBio's own release states the $50M Series B+.
1 source
Sources agree. The release names an unnamed strategic investor but does not identify a firm or person, so it is not included in the investor list.
2 sources
Sources agree. The release states that InnoPinnacle Fund was an existing investor, but it explicitly identifies the fund as the lead of this Series A round.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $120M $360M to date | 2026-08-27 | not stated | No recent discussion |
8 sources · checked 1 time, last 42d ago [ VERIFIED · CORRECTED ] read against 4 of 8 sources
The company release says an unnamed strategic investor led the financing and names RA Capital as a participant; Fierce says RA Capital led. The company release takes precedence. | ||||
AusperBio develops targeted oligonucleotide medicines for chronic diseases, initially aiming to make a functional cure for chronic hepatitis B.
Chronic hepatitis B remains a major global health burden, while current therapies can suppress viral replication without delivering a functional cure and often leave patients on long-term treatment. AusperBio says AHB-137 has shown promising clinical activity and is advancing through Phase 3 in China, while its $120 million Series C is intended to support commercialization readiness and next-generation HBV programs.
Checked against 10 sources on Sep 24
| Series B Series B2 [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63M | 2025-09-22 | Qiming Venture Partners | No recent discussion |
1 source [ VERIFIED ] read against 1 source Sources agree. Published by hand (finsmes.com): "HomeUSAAusperBio Raises $63M in Series B2 Funding": Checked by hand: FinSMEs states the $63M Series B2. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: finsmes.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B Series B+ [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $50M | 2025-05-28 | not stated | No recent discussion |
1 source [ VERIFIED ] read against 1 source The source's page date is 2025-05-29, but the company's press-release dateline is May 28, 2025, which fixes the announcement date. The round was led by an unnamed existing industry-leading VC investor, so no named lead is listed; the six named firms are described as participating investors. Published by hand (ausperbio.com): "AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B": Checked by hand: AusperBio's own release states the $50M Series B+. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: ausperbio.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $73M | 2024-12-26 | HanKang Capital | No recent discussion |
1 source [ VERIFIED ] read against 1 source Sources agree. The release names an unnamed strategic investor but does not identify a firm or person, so it is not included in the investor list. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $37M | 2024-07-14 | InnoPinnacle Fund | No recent discussion |
2 sources [ VERIFIED ] read against 1 of 2 sources Sources agree. The release states that InnoPinnacle Fund was an existing investor, but it explicitly identifies the fund as the lead of this Series A round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: ausperbio.com, prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||